| Literature DB >> 29986693 |
Alex J Walker1, Seb Bacon1, Richard Croker1, Ben Goldacre2.
Abstract
BACKGROUND: The widely used OpenPrescribing.net service provides standard measures which compare prescribing of Clinical Commissioning Groups (CCGs) and English General Practices against that of their peers. Detecting changes in prescribing behaviour compared with peers can help identify missed opportunities for medicines optimisation. Automating the process of detecting these changes is necessary due to the volume of data, but challenging due to variation in prescribing volume for different measures and locations. We set out to develop and implement a method of detecting change on all individual prescribing measures, in order to notify CCGs and practices of such changes in a timely manner.Entities:
Keywords: CUSUM; Change detection; Prescribing data
Mesh:
Year: 2018 PMID: 29986693 PMCID: PMC6038291 DOI: 10.1186/s12911-018-0642-6
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Fig. 1Graphs showing an example measure used to develop the alerts. Showing: a the measure as on openprescribing.net: Cerazette vs. desogestrel in 05D, b the percentiles with alerts highlighted for the standard method, c the cumulative sum, with threshold values for the standard method, d the percentiles with alerts highlighted for the continuing change method, e the cumulative sum, with threshold values for the continuing change method. Increase alerts all lie above the reference percentile line, while decrease alerts all lie below it
Fig. 2CCG examples. Graphs showing the measures for CCGs as shown on openprescribing.net (i), percentiles with alerts highlighted (ii) and the cumulative sum, with threshold values (iii). Examples are: a high-cost ace inhibitors in 99P, b topical treatment of fungal nail infections in 09 J, c high dose inhaled corticosteroids in 07 M, d antibiotic stewardship: volume of antibiotic prescribing (KTT9) in 09 J. Increase alerts all lie above the reference percentile line, while decrease alerts all lie below it
Fig. 3Practice examples. Graphs showing the measures for practices as shown on openprescribing.net (i), percentiles with alerts highlighted (ii) and the cumulative sum, with threshold values (iii). Examples are: a Cerazette vs. desogestrel in N85051, b glaucoma eye drops prescribed by brand in J83041, c high-cost statins in N82073, d non-preferred NSAIDs and COX-2 inhibitors (KTT13) in Y02735. Increase alerts all lie above the reference percentile line, while decrease alerts all lie below it
Fig. 4Histograms showing the distribution of the number of alerts received by each CCG (a and b) and practice (c and d) in the last month
Percentage of institutions receiving alerts, by measure
| CCGs | Practices | |||
|---|---|---|---|---|
| Measure | Increase alerts, % last month (mean) | Decrease alerts, % last month (mean) | Increase alerts, % last month (mean) | Decrease alerts, % last month (mean) |
|
|
|
|
|
|
|
|
|
|
|
|
| Topical treatment of fungal nail infections | 5.3 | 6.2 | 2.1 | 2.9 |
| High-cost PPIs | 7.2 | 7.2 | 3.1 | 3.9 |
| High cost tramadol preparations | 2.4 | 3.3 | 4.6 | 4.4 |
| High-cost drugs for erectile dysfunction | 6.2 | 6.7 | 3.7 | 4.4 |
| High-cost ARBs | 6.7 | 4.3 | 2.7 | 2.7 |
| High dose inhaled corticosteroids | 14.4 | 12.9 | 5.8 | 5.1 |
| Prescribing of dipyridamole | 7.7 | 7.7 | 5.0 | 5.0 |
| Methotrexate 10 mg tablets | 5.3 | 7.7 | 2.7 | 3.1 |
| Vitamin B complex | 16.3 | 8.6 | 5.0 | 5.0 |
| Soluble/effervescent forms of paracetamol and co-codamol | 6.7 | 3.3 | 4.0 | 4.2 |
| Non-preferred NSAIDs and COX-2 inhibitors | 2.9 | 4.3 | 3.4 | 4.4 |
| Other lipid-modifying drugs | 8.1 | 6.7 | 4.7 | 3.9 |
| Direct Oral Anticoagulants (DOACs) | 14.4 | 15.3 | 4.5 | 4.9 |
| Silver dressings | 5.3 | 5.7 | 2.8 | 3.2 |
| Long-acting insulin analogues | 6.7 | 7.7 | 3.2 | 3.9 |
| Volume of antibiotic prescribing | 5.3 | 4.8 | 4.9 | 5.0 |
| Prescribing of pregabalin | 12.0 | 12.9 | 5.6 | 5.4 |
| Diltiazem preparations prescribed generically | 12.0 | 12.4 | 4.0 | 6.6 |
| Co-proxamol | 8.1 | 5.3 | 1.0 | 4.6 |
| High dose opioids | 4.8 | 6.2 | 5.8 | 5.5 |
| Ciclosporin and tacrolimus oral preparations prescribed generically | 2.9 | 5.7 | 1.4 | 2.2 |
| Desogestrel prescribed as a branded product | 11.5 | 12.4 | 4.6 | 6.2 |
| Nebivolol 2.5mg tablets | 7.2 | 6.7 | 3.1 | 2.6 |
| Three-day antibiotic courses for UTIs | 3.8 | 2.9 | 2.9 | 3.5 |
| High-cost ACE inhibitors | 2.4 | 2.4 | 1.7 | 3.0 |
| High-cost statins | 4.8 | 8.6 | 3.4 | 3.9 |
| Glaucoma eye drops prescribed by brand | 12.0 | 9.1 | 4.0 | 4.8 |
| Higher dose Proton Pump Inhibitors | 14.8 | 12.9 | 7.1 | 8.3 |
| Co-amoxiclav, cephalosporins & quinolones | 11.0 | 8.6 | 4.6 | 4.8 |
| Extended-release quetiapine | 11.5 | 7.7 | 6.2 | 5.9 |
| Short acting beta agonist inhalers | 3.8 | 8.6 | 3.5 | 3.0 |
| Keppra vs. levetiracetam | 5.3 | 4.3 | 3.3 | 2.7 |
Bold figures are summary numbers for all measures, non-bold are figures for each separate measure